Alamos Gold Inc. (AGI) Reaches $6.12 After 4.00% Up Move; American Physicians Service Group Has 0.91 Sentiment

January 14, 2018 - By Adrian Erickson

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $853.31 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

The stock of Alamos Gold Inc. (NYSE:AGI) is a huge mover today! The stock increased 3.90% or $0.23 during the last trading session, reaching $6.12. About 2.53 million shares traded or 24.26% up from the average. Alamos Gold Inc. (NYSE:AGI) has declined 3.35% since January 14, 2017 and is downtrending. It has underperformed by 20.05% the S&P500.The move comes after 5 months positive chart setup for the $2.35B company. It was reported on Jan, 14 by Barchart.com. We have $6.36 PT which if reached, will make NYSE:AGI worth $93.80M more.




Analysts await Alamos Gold Inc. (NYSE:AGI) to report earnings on February, 22. They expect $0.01 EPS, up 133.33% or $0.04 from last year’s $-0.03 per share. AGI’s profit will be $3.83 million for 153.00 P/E if the $0.01 EPS becomes a reality. After $0.05 actual EPS reported by Alamos Gold Inc. for the previous quarter, Wall Street now forecasts -80.00% negative EPS growth.

Among 9 analysts covering Alamos Gold (NYSE:AGI), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Alamos Gold had 24 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Thursday, May 25. The firm has “Outperform” rating by National Bank Canada given on Friday, May 27. On Thursday, March 10 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The firm earned “Hold” rating on Tuesday, May 3 by Canaccord Genuity. RBC Capital Markets maintained the shares of AGI in report on Tuesday, October 10 with “Hold” rating. As per Tuesday, March 29, the company rating was downgraded by Scotia Capital. The rating was upgraded by IBC to “Sector Outperform” on Wednesday, August 19. RBC Capital Markets upgraded the shares of AGI in report on Monday, December 12 to “Outperform” rating. The firm has “Outperform” rating by Raymond James given on Monday, June 27. The stock of Alamos Gold Inc. (NYSE:AGI) earned “Hold” rating by RBC Capital Markets on Monday, July 31.

Alamos Gold Inc., together with its subsidiaries, engages in the acquisition, exploration, development, and extraction of gold deposits in North America. The company has market cap of $2.35 billion. It also explores for silver and precious metals. It has a 204 P/E ratio. The firm holds interests in the Young-Davidson mine, which includes contiguous mineral leases and claims totaling 11,000 acres located in Northern Ontario, Canada; the Mulatos mine located within the Salamandra Concessions in the Sierra Madre Occidental mountain range in the east-central portion of the State of Sonora, Mexico; and the El Chanate mine that comprises 22 mineral concessions covering 4,618 hectares situated in the State of Sonora, Mexico.

Argent Capital Management Llc holds 0.08% of its portfolio in Amphastar Pharmaceuticals, Inc. for 121,275 shares. Matarin Capital Management Llc owns 52,417 shares or 0.08% of their US portfolio. Moreover, Piermont Capital Management Inc. has 0.08% invested in the company for 13,490 shares. The New York-based Rothschild Asset Management Inc has invested 0.07% in the stock. Federated Investors Inc Pa, a Pennsylvania-based fund reported 1.05 million shares.

Analysts await Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report earnings on March, 12. They expect $-0.04 EPS, up 33.33% or $0.02 from last year’s $-0.06 per share. After $0.07 actual EPS reported by Amphastar Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -157.14% negative EPS growth.

The stock increased 2.20% or $0.4 during the last trading session, reaching $18.56. About 170,652 shares traded. Amphastar Pharmaceuticals, Inc. (AMPH) has risen 8.19% since January 14, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: